Isothermal Nucleic Acid Amplification Technology Market Share, Size, Trends, Industry Analysis Report, By Product (Assay, Kits, Reagents and Systems); By Type; By Application; By End-Use; By Region; Segment Forecast, 2022 - 2030
- Published Date:Oct-2022
- Pages: 114
- Format: PDF
- Report ID: PM2670
- Base Year: 2021
- Historical Data: 2018 - 2020
Report Outlook
The global isothermal nucleic acid amplification technology market was valued at USD 3.71 billion in 2021 and is expected to grow at a CAGR of 12.2% during the forecast period. The growing demand for isothermal nucleic acid amplification technology is expected to be driven by the increasing occurrence of antimicrobial and infectious diseases and growing R&D funding to develop innovative automated diagnostic devices.
Know more about this report: Request for sample pages
Isothermal nucleic acid amplification technology is quick, sensitive, and provides accurate results, as being isothermal by nature requires minimal resources to detect and target the substance. This method is replacing the traditional method, i.e., polymerase chain reaction, as it amplifies with less energy, works without thermal cycles, and is portable, driving the isothermal nucleic acid amplification technology market's demand.
The COVID-19 pandemic positively impacted the growth of the Isothermal nucleic acid amplification technology market. The rise in RT-PCR testing was at its peak, which needed quick and accurate results to detect the virus, which increased the demand in clinics. For instance, Abbott launched a POC test to detect a novel coronavirus that gives results within 5-13 minutes.
Furthermore, the isothermal technology operates at a set temperature depending upon the type of nucleic acid; the accessibility of this method to different economic levels due to its low cost is increasing the demand for the product. However, developing regions' lack of awareness and stringent regulatory framework can restrain the isothermal nucleic acid amplification technology market growth.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
The demand for isothermal nucleic acid amplification technology is increasing owing to the consumer shift for diagnostic devices which are user-friendly, quick, and disease-specific. Furthermore, rising disposable income and development in healthcare infrastructure across developing nations are likely to have a positive impact on the market growth for the isothermal nucleic acid amplification technology.
Moreover, the rising infectious disease has resulted in the development of a gene-based drug which has increased the demand for low-cost drugs and treatment for genetic disorders. In addition, the miniaturization of nucleic-acid diagnosis is also a significant factor responsible for the market growth of isothermal nucleic acid amplification technology.
Report Segmentation
The market is primarily segmented based on product, type, application, end-use, and region.
|
By Product |
By Type |
By Application |
By End-Use |
By Region |
· |
· |
|
· |
|
Know more about this report: Request for sample pages
Assay, kits and reagents segment accounted for the largest share in 2021
Assay, kits, and reagents segment accounted for the highest revenue share in 2021 owing to the accessibility of a variety of reagents to treat the growing number of infectious diseases. Rising cases of cardiovascular disorder, glucose, and cholesterol illness are resulting in the development of POC diagnostic devices, which are convenient and give quick results which are supporting segment growth.
Furthermore, increasing diagnostic tests and approval of CLIA-waived tests as they are simple and have fewer errors as well as helpful in adjusting the medicine dosages of patients is also contributing to the growth of isothermal nucleic acid amplification technology.
Transcription-mediated amplificationis expected to lead the market
The demand for transcription-mediated amplification is driven by the isothermal nature, which reduces the chances of transfer of contamination in clinical laboratories. The growing demand for TMA is due to its extremely fast kinetics, and it can amplify a substance billion times within 20-60 minutes. In addition, the growing demand is observed in blood banks as TMA is more sensitive and efficient in determining hemoglobin levels in the blood, which is likely to complement market growth of nucleic acid amplification technology.
Infectious disease diagnosis is expected to witness fastest growth over the forecast period
The rising prevalence of infectious diseases such as hepatitis, HIV, herpes, and influenza and their effective diagnosis and treatment with nucleic acid amplification kits is expected to drive market growth. The rising POC diagnostic tests help to manage, treat and allow doctors to monitor the infectious disease at an early stage which supports the market growth. Moreover, antimicrobial and epidemic outbreaks are receiving more attention which is likely to have a positive impact on the market growth over the forecast period.
Hospital segment is expected to account for the largest share in 2030
The hospital segment is expected to dominate the market over the forecast period owing to the increasing usage of INAAT kits for treating the disease. Furthermore, most of the diagnostic procedures are carried out under supervision which reduces chances of error and accurate results, which is likely to have a positive impact on the revenue growth over the forecast period. In addition, the demand for nucleic acid amplification technology is increasing in hospitals than other end-use industries, which is driving the segment growth.
North America is expected to dominate and witness fastest growth over the forecast period
North America is the largest region for isothermal nucleic acid amplification technology and is expected to witness faster growth over the forecast period owing to rising genetic disorders such as cystic fibrosis, sickle cell, autism, and many more among the young population.
The R&D investments by many key players to develop genome-based drugs are driving market growth. In addition, rising concerns about infectious diseases among the geriatric population and cost-effective diagnosis have created a demand for the product, which is expected to drive demand over the forecast period.
Competitive Insight
Some of the major players operating in the global market include Abbott, Alere Inc., Becton, Dickson & Company, Biohelix Corporation, Biomerieux Biotechnology Company, Eiken Chemical Co. Ltd, Grifols S.A., Hologic Gene-Probe, Lucigen Corporation, Meridian Biosciences, Inc., Nugen, Optigene Limited, QIAGEN Company, Quidel Corporation, Tecan Genomics Inc., Thermos Fisher Scientific, Inc., Ustar Biotechnologies Ltd.
Recent Developments
In May 2022,Meridian bioscience, inc., expanded its product line of isothermal amplification named Lyo-Ready Direct DNA LAMP saliva mix and Lyo-Ready Direct RNA/DNA LAMP saliva mix which are majorly used in molecular diagnostic.
In March 2022, Thermo fisher scientific had launched two new reverse transcription loop-mediated isothermal amplification-based products that offers a quick and affordable method for detecting viral pathogens
Isothermal Nucleic Acid Amplification Technology Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2022 |
USD 4.11 billion |
|
Revenue forecast in 2030 |
USD 10.34 billion |
|
CAGR |
12.2% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Product, By Type, By Application, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Abbott, Alere Inc., Becton, Dickson & Company, Biohelix Corporation, Biomerieux Biotechnology Company, Eiken Chemical Co. Ltd, Grifols S.A., Hologic Gene-Probe, Lucigen Corporation, Meridian Biosciences, Inc., Nugen, Optigene Limited, QIAGEN Company, Quidel Corporation, Tecan Genomics Inc., Thermos Fisher Scientific, Inc., Ustar Biotechnologies Ltd.
|
© 2024 Polaris Market Research and Consulting. All rights reserved
